Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAC698)

Drug Name
CORILAGIN Drug Info
Synonyms
Corilagin; 23094-69-1; CHEMBL449392; CHEBI:3884; TUSDEZXZIZRFGC-XIGLUPEJSA-N; Corillagin; Corilagin,(S); AC1Q6PBU; AC1L2K3M; (1s,19r,21s,22r,23r)-6,7,8,11,12,13,22,23-octahydroxy-3,16-dioxo-2,17,20-trioxatetracyclo[17.3.1.04,9.010,15]tricosa-4,6,8,10,12,14-hexaen-21-yl 3,4,5-trihydroxybenzoate; SCHEMBL329080; Corilagin, analytical standard; CTK4F0871; MolPort-020-005-758; b-D-Glucopyranose, cyclic3,6-[(1R)-4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate]1-(3,4,5-trihydroxybenzoate); ZINC4098612; BDBM50242279
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
73568
ChEBI ID
CHEBI:3884
CAS Number
CAS 2088321-44-0
TTD Drug ID
DMAC698

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Human immunodeficiency virus Reverse transcriptase (HIV RT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [3]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [4]
Zalcitabine DMH7MUV Human immunodeficiency virus infection 1C62 Approved [5]
Tenofovir DM1IS6U Human immunodeficiency virus infection 1C62 Approved [3]
Lamivudine DMI347A Chronic HBV infection 1E51.0Z Approved [6]
Abacavir DMMN36E Human immunodeficiency virus infection 1C62 Approved [7]
Delavirdine DM3NF5G Human immunodeficiency virus infection 1C62 Approved [6]
Efavirenz DMC0GSJ Human immunodeficiency virus infection 1C62 Approved [6]
Rilpivirine DMJ0QOW Human immunodeficiency virus infection 1C62 Approved [8]
Etravirine DMGV8QU Human immunodeficiency virus-1 infection 1C62 Approved [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Squalene monooxygenase (SQLE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Naftifine DMHVBG1 Dermatomycosis EA60 Approved [10]
Tolnaftate DM28MU7 Dermatophytosis 1F28.2 Approved [11]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [1]
FR-194738 DMNACIV Hypercholesterolaemia 5C80.0 Terminated [12]
SDZ-87-469 DMBY6CQ Coronary artery disease BA80 Terminated [11]
NB-598 DMJVTQN N. A. N. A. Terminated [13]
ELLAGIC ACID DMX8BS5 Discovery agent N.A. Investigative [1]
1,2,3,4,6-penta-O-galloyl-beta-D-glucose DMTK650 Discovery agent N.A. Investigative [1]
Pedunculagin DMKLRCX Discovery agent N.A. Investigative [1]
Ethylgallate DMJ6PB8 Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Inhibitor [2]
Squalene monooxygenase (SQLE) TTE14XG ERG1_HUMAN Inhibitor [1]

References

1 Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
2 HIV and reverse transcriptase inhibition by tanninsOriginal Research. Bioorg. Med. Chem. Lett. 2(12):1529-1534 (1992).
3 Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
4 HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
5 A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
8 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
9 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
10 Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):443-7.
11 Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrob Agents Chemother. 1992 Aug;36(8):1779-81.
12 Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738. Bioorg Med Chem Lett. 2004 Feb 9;14(3):633-7.
13 Squalene epoxidase as hypocholesterolemic drug target revisited. Prog Lipid Res. 2003 Jan;42(1):37-50.